Well, they started enrolling in early February I believe. Since it's the Kidney Cancer Consortium and happening at MD Anderson, and it's first line disease, I'm assuming they'll be able to get patients enrolled fairly quickly.
Phase 1B is only 15 patients, stage 4 metastatic RCC patients with no prior treatments are eligible. This is a pretty sick pool. They're going to be looking for increased ORR over standard of care. My rough guess is that if the combo works they way Corvus hopes it does based on the way it looked in preclinical, with no serious safety flags, we'll start hearing about that by early fall.
I don't think investors are giving Corvus any value for this right now. That could change in a hurry.
News 
Market Data 
Discover 
